We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Israeli drugmaker Can-Fite BioPharma announced that it has begun Phase IIb clinical trials of its drug CF101 for the treatment of rheumatoid arthritis.
Indian drugmaker Aurobindo Pharma has acquired an FDA-compliant facility in Dayton, N.J. The facility spans 20 acres in the Princeton Life Sciences Corridor.
Ranbaxy's Spanish subsidiary, Laboratorios Ranbaxy, has acquired GlaxoSmithKline's (GSK) Spanish generic business, Mundogen, the company announced. No other details on the acquisition were disclosed.
Japan-based Astellas Pharma and Theravance have agreed to add Japan to their list of countries in which to develop and commercialize Theravance's investigational antibiotic, telavancin, giving Astellas worldwide rights to this drug candidate.
The Competition Board on Thursday ruled that the pharmaceutical companies Roche and Eczacibasi, and Beser Pharmacy Retailers pay YTL 10 million in fines.
Synexus Clinical Research, the world's largest multinational company specialising in the recruitment and running of late stage clinical trials, has cemented its market-leading position by adding a clinical trials centre in Hungary to its growing portfolio of more than 15 hub sites in the UK, Eastern Europe and India.
Glenmark Pharmaceutical (UK) Ltd, a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark) and Generics (UK) Limited, on behalf of the Merck Generics Group (Merck Generics), a subsidiary of Merck KGaA of Darmstadt, Germany, have entered into an agreement for the joint development, filing and marketing of 8 generic dermatological products for Europe, which have a current annual sales value of around USD 225 million in the region.